Christine N Manser1, Pascal Frei, Tanja Grandinetti, Luc Biedermann, Jessica Mwinyi, Stephan R Vavricka, Alain Schoepfer, Michael Fried, Gerhard Rogler. 1. *Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland; †Gastroenterology Unit, Clinic of Internal Medicine, See-Spital, Horgen, Switzerland; ‡Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland; §Department of Gastroenterology and Hepatology, Triemlispital Zurich, Zurich, Switzerland; and ‖Division of Gastroenterology and Hepatology, University Hospital Lausanne/CHUV, Lausanne, Switzerland.
Abstract
BACKGROUND: Surgical recurrence rates among patients with Crohn's disease with ileocolic resection (ICR) remain high, and factors predicting surgical recurrence remain controversial. We aimed to identify risk and protective factors for repetitive ICRs among patients with Crohn's disease in a large cohort of patients. METHODS: Data on 305 patients after first ICR were retrieved from our cross-sectional and prospective database (median follow-up: 15 yr [0-52 yr]). Data were compared between patients with 1 (ICR = 1, n = 225) or more than 1 (ICR >1, n = 80) resection. Clinical phenotypes were classified according to the Montreal Classification. Gender, family history of inflammatory bowel disease, smoking status, type of surgery, immunomodulator, and biological therapy before, parallel to and after first ICR were analyzed. RESULTS: The mean duration from diagnosis until first ICR did not differ significantly between the groups, being 5.93 ± 7.65 years in the ICR = 1 group and 5.36 ± 6.35 years in the ICR >1 group (P = 0.05). Mean time to second ICR was 6.7 ± 5.74 years. In the multivariate logistic regression analysis, ileal disease location (odds ratio [OR], 2.42; 95% confidence interval [CI], 1.02-5.78; P = 0.05) was a significant risk factor. A therapy with immunomodulators at time of or within 1 year after first ICR (OR, 0.23; 95% CI, 0.09-0.63; P < 0.01) was a protective factor. Neither smoking (OR, 1.16; 95% CI, 0.66-2.06) nor gender (male OR, 0.85; 95% CI, 0.51-1.42) or family history (OR, 1.68; 95% CI, 0.84-3.36) had a significant impact on surgical recurrence. CONCLUSIONS: Immunomodulators have a protective impact regarding surgical recurrence after ICR. In contrast, ileal disease location constitutes a significant risk factor for a second ICR.
BACKGROUND: Surgical recurrence rates among patients with Crohn's disease with ileocolic resection (ICR) remain high, and factors predicting surgical recurrence remain controversial. We aimed to identify risk and protective factors for repetitive ICRs among patients with Crohn's disease in a large cohort of patients. METHODS: Data on 305 patients after first ICR were retrieved from our cross-sectional and prospective database (median follow-up: 15 yr [0-52 yr]). Data were compared between patients with 1 (ICR = 1, n = 225) or more than 1 (ICR >1, n = 80) resection. Clinical phenotypes were classified according to the Montreal Classification. Gender, family history of inflammatory bowel disease, smoking status, type of surgery, immunomodulator, and biological therapy before, parallel to and after first ICR were analyzed. RESULTS: The mean duration from diagnosis until first ICR did not differ significantly between the groups, being 5.93 ± 7.65 years in the ICR = 1 group and 5.36 ± 6.35 years in the ICR >1 group (P = 0.05). Mean time to second ICR was 6.7 ± 5.74 years. In the multivariate logistic regression analysis, ileal disease location (odds ratio [OR], 2.42; 95% confidence interval [CI], 1.02-5.78; P = 0.05) was a significant risk factor. A therapy with immunomodulators at time of or within 1 year after first ICR (OR, 0.23; 95% CI, 0.09-0.63; P < 0.01) was a protective factor. Neither smoking (OR, 1.16; 95% CI, 0.66-2.06) nor gender (male OR, 0.85; 95% CI, 0.51-1.42) or family history (OR, 1.68; 95% CI, 0.84-3.36) had a significant impact on surgical recurrence. CONCLUSIONS: Immunomodulators have a protective impact regarding surgical recurrence after ICR. In contrast, ileal disease location constitutes a significant risk factor for a second ICR.
Authors: Kelli L VanDussen; Aleksandar Stojmirović; Katherine Li; Ta-Chiang Liu; Patrick K Kimes; Brian D Muegge; Katherine F Simpson; Matthew A Ciorba; Jacqueline G Perrigoue; Joshua R Friedman; Jennifer E Towne; Richard D Head; Thaddeus S Stappenbeck Journal: Gastroenterology Date: 2018-05-18 Impact factor: 22.682
Authors: Ellen Li; Yuanhao Zhang; Xinyu Tian; Xuefeng Wang; Grace Gathungu; Ashley Wolber; Shehzad S Shiekh; R Balfour Sartor; Nicholas O Davidson; Matthew A Ciorba; Wei Zhu; Leah M Nelson; Charles E Robertson; Daniel N Frank Journal: PLoS One Date: 2019-02-28 Impact factor: 3.240
Authors: Sung Bae Kim; Jae Hee Cheon; Jae Jun Park; Eun Soo Kim; Seong Woo Jeon; Sung-Ae Jung; Dong Il Park; Chang Kyun Lee; Jong Pil Im; You Sun Kim; Hyun Soo Kim; Jun Lee; Chang Soo Eun; Jeong Mi Lee; Byung Ik Jang; Geom Seog Seo Journal: Gut Liver Date: 2020-05-15 Impact factor: 4.519